180576-04-9

Usage

Uses

Used in Pharmaceutical Research and Development:
TERT-BUTYL 4-(2-TERT-BUTOXY-2-OXOETHYL)PIPERAZINE-1-CARBOXYLATE is used as a building block for the synthesis of novel pharmaceutical compounds, particularly for the development of drugs targeting neurological and psychiatric disorders. Its unique structure and properties make it a valuable starting material for creating new drug candidates.
Used in Medication Creation:
In the pharmaceutical industry, TERT-BUTYL 4-(2-TERT-BUTOXY-2-OXOETHYL)PIPERAZINE-1-CARBOXYLATE is used as a key component in the formulation of new medications. Its role in the synthesis process is crucial for the development of innovative treatments for various neurological and psychiatric conditions.
Used in Drug Synthesis:
TERT-BUTYL 4-(2-TERT-BUTOXY-2-OXOETHYL)PIPERAZINE-1-CARBOXYLATE is used as a starting material in drug synthesis, allowing researchers to explore and create new chemical entities with potential therapeutic benefits. Its versatility in chemical reactions facilitates the design and development of a wide range of pharmaceutical agents.

InChI:InChI=1/C15H28N2O4/c1-14(2,3)20-12(18)11-16-7-9-17(10-8-16)13(19)21-15(4,5)6/h7-11H2,1-6H3

Upstream product

• 77278-40-1 tert-butyl 4-(benzoyloxy)piperazine-1-carboxylate 
• 540-88-5 acetic acid tert-butyl ester 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 37478-58-3 N'-(carboxymethyl)-piperazine 

Relevant academic research and scientific papers

TARGETING COMPOUNDS

The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION

The present invention provides novel compounds having general formula (I), wherein R1 to R4, A, W, Q and Y are as described herein, compositions including the compounds and methods of using the compounds.

Selective α-amination and α-acylation of esters and amides via dual reactivity of O-acylhydroxylamines toward zinc enolates

Selective α-amination and α-acylation of esters and amides have been developed, employing O-acylhydroxylamines as a dually reactive aminating and acylating reagent. Treatment of zinc enolates with O-acylhydroxylamines provides solely 1,3-dicarbonyl compounds under mild conditions. Introduction of a copper catalyst into the system shifts the reactivity entirely, yielding α-amination products exclusively.

Novel inhibitors of bacterial biofilms and related methods

Multi-cyclic compounds of chemical structure represented by formula given below and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.

Inhibitors of bacterial biofilms and related methods

Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.